Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Clinical Trial of Molecular Therapy for Muscular Dystrophy Yields Significant Positive Results

Published: Tuesday, July 26, 2011
Last Updated: Monday, July 25, 2011
Bookmark and Share
A molecular technique originally developed at the University of North Carolina at Chapel Hill has taken one step closer to becoming a treatment for the devastating genetic disease Duchenne muscular dystrophy.

A molecular technique originally developed at the University of North Carolina at Chapel Hill has taken one step closer to becoming a treatment for the devastating genetic disease Duchenne muscular dystrophy.

The novel treatment uses strips of genetic code - called antisense oligonucleotides - to restore the function of a defective dystrophin gene. In a study published July 25, 2011 in the journal The Lancet, researchers from the U.K., U.S. and Australia demonstrated that a phase Ib/IIa trial of the approach restored production of the critical muscle protein missing in patients with the progressive neuromuscular condition.

“When I first tried my approach in a test tube some twenty years ago, a reviewer of my manuscript commented that it was ‘molecular gymnastics that will never amount to anything,’” said study co-author Ryszard Kole, PhD, a professor of pharmacology who has taken a leave of absence from UNC to develop the technology with AVI Biopharma, in Bellevue, Washington. “Now we have evidence that it works, and in an illness that has no other good therapeutic options.”

Duchenne muscular dystrophy is a lethal disease that affects 1 in 3500 newborn boys. In the disease, omissions or misprints in the letters of the dystrophin gene cause its “reading frame” to shift, abbreviating the instructions for making the dystrophin protein.

As a result, the cells fail to make a functional muscle protein and patients eventually lose their ability to walk and breathe. In a milder form of the disease, called Becker muscular dystrophy, the genetic defect leads to one missed component but leaves the rest intact, resulting in a muscle protein that is largely functional and patients that can have a normal lifespan.

In the current study, the researchers tested a way to turn the lethal to the livable form of the illness by using antisense oligonucleotides, strings of genetic lettering that can stick to and mask sections of code.

The oligonucleotides cause the cell’s “splicing” machinery - responsible for cutting and pasting the instructions together - to skip a few paragraphs so the reading frame is back on track and the rest of the dystrophin protein can be made as instructed.

To prove this concept, the scientists administered the treatment intraveneously (IV) to 19 Duchenne muscular dystrophy patients over the course of 12 weeks. They found that the drug was well tolerated and appeared to increase the levels of dystrophin protein in a statistically significant dose-dependent manner.

The best 3 responders showed an increase following treatment of protein levels from 2 percent to 18 percent, from 0.9 percent to17 percent and from 0 percent to 7.7 percent of normal muscle, respectively.

They now plan to expand their studies in a next trial, increasing both the dose and the duration of the treatment to see if the approach has clinical impact. In the future the researchers would like to develop alternative formulations of the drug that can be administered subcutaneously, like for diabetes, or perhaps even in pill form.

But Kole says even the current approach holds great promise for the over 30,000 people who have the illness worldwide.

“If I get to see one child benefit from this treatment, it will be a life as a scientist well spent,” said Kole.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Researchers Find Two Biomarkers Linked to Severe Heart Disease
Study suggests that elevated oxidized LDL cholesterol and fructosamine – a measure of glycated proteins in blood sugar – are signposts for the development of severe coronary disease, especially in females.
Thursday, July 09, 2015
A Single-Cell Breakthrough
UNC School of Medicine scientist Scott Magness and collaborators use their newly developed technology to dissect properties of single stem cells. The advancement will allow researchers to study gastrointestinal disorders and cancers like never before.
Thursday, March 19, 2015
New Gene Therapy For Hemophilia Shows Potential As Safe Treatment
Research showed that bleeding events were drastically decreased in animals with hemophilia B. Using a viral vector to swap out faulty genes proved safe and could be used for the more common hemophilia A.
Tuesday, March 17, 2015
Genetically Speaking, Mammals Are More Like Their Fathers
A first of its kind study shows that who we inherit genetic variants from – our mother or father – is crucial for the development of diseases and for research studies aimed at finding causes and potential treatments.
Wednesday, March 04, 2015
Key Protein That Allows Plavix To Conquer Platelets Found
The findings could lead to more personalized approaches to controlling platelet activity during heart attacks and other vascular emergencies and diseases.
Wednesday, February 25, 2015
Researchers Silence Leading Cancer-Causing Gene
A novel siRNA-based molecule successfully targets KRAS, a well-studied but hard to halt protein important for cancer development and metastasis.
Monday, November 17, 2014
Blood Test May Help Determine Psychosis Risk
A study led by University of North Carolina at Chapel Hill researchers represents an important step forward in the accurate diagnosis of people who are experiencing the earliest stages of psychosis.
Tuesday, September 23, 2014
New Gene Therapy Proves Promising as Hemophilia Treatment
Researchers package specialized blood platelets with genes that express clotting factor, leading to fewer bleeding events.
Wednesday, December 18, 2013
New Findings Regarding DNA Damage Checkpoint Mechanism in Oxidative Stress
Scientists uncover previously unknown surveillance mechanism.
Thursday, June 20, 2013
Medical Diagnostics Company STAT-Diagnostica Secures $22.1 Million in Financing
Proceeds will be used to complete development of the company’s Near Patient Testing diagnostic system and clinical validation of its first products.
Tuesday, May 07, 2013
Researchers Pinpoint How Trees Play Role in Smog Production
After years of scientific uncertainty and speculation, researchers show exactly how trees help create one of society’s predominant environmental and health concerns: air pollution.
Tuesday, May 07, 2013
Molecular Twist Helps Regulate the Cellular Message to Make Histone Proteins
Researchers show for the first time how two key proteins in messenger RNA communicate via a molecular twist to help maintain the balance of histones to DNA.
Monday, January 21, 2013
Informatics Approach Helps Doctors, Patients Make Sense of Genome Data
Researchers from UNC unveil an analysis framework aimed at helping clinicians spot “medically actionable findings” from genetic tests in an efficient manner.
Friday, September 21, 2012
Identifying Protein 'Pockets' that Block Hallucinogens
Psychoactive drugs work by binding proteins in our brains and bodies and although these proteins have been a mystery, new research from the University of North Carolina is illuminating their structures.
Wednesday, August 01, 2012
Molecular Delivery Truck Serves Gene Therapy Cocktail
University of North Carolina scientists have devised a gene therapy cocktail that has the potential to treat some inherited diseases associated with “misfolded” proteins.
Tuesday, August 23, 2011
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!